Fusion Antibodies has developed a novel affinity maturation platform (RAMP™) for the rapid optimisation of your antibody building upon more than 17 years’ experience in antibody engineering and humanization.
Affinity maturation is the natural process by which immunoglobulins undergo somatic hypermutation and selection, as part of the adaptive immune response, in order to increase their binding affinity to their target antigen.
Fusion Antibodies’ RAMP™ platform adopts lessons from nature and combines a rational approach to library design, with rapid in silico selection for both improved binding potential and predicted stability. The result is that we will generate an enriched ‘micro-library’ of variants with improved stability and affinity for the target.
or contact us below
Using our proprietary library design, we explore the natural somatic hypermutation space of your antibody sequence, identifying motifs that are susceptible to mutation. Our library design incorporates mutations in both the framework and complementarity determining regions (CDRs) of the antibody. Framework diversity has been a key factor in the success of the Fusion Antibodies CDRx™ humanization platform and is critical in making this the most efficient affinity maturation platform available to the market.
Furthermore, our library design algorithms explicitly filter candidate sequences including sequence liabilities, which is important for the downstream manufacturability and cost of goods (COGs) of the selected antibodies.
Using in silico modelling and molecular docking we interrogate the library of antibody variants, selecting those with predicted improvements in both binding potential and stability. Balance of function and developability is a key principle of RAMP™.
This rapid selection approach enables us to focus a library of >1015 variants down to approx. 100 sequences. Due to the manageable number of variants they can be expressed in a full IgG format in mammalian cells which negates any selection bias that can occur with phage display approaches that require a scFv format and bacterial expression.
The enriched library (of approx. 100 variants) is expressed in the full IgG format in CHO cells and purified prior to in vitro characterisation. Target binding (ELISA, BLI), expression yield and stability (DSF) are assessed for each antibody variant and parental control. Specificity, aggregation propensity and other biophysical characteristics may also be assessed at this stage.
A high proportion of expressed mAbs display improved affinity compared to the parental mAb; offering a rich pool for selection of your lead candidate antibody or start point for repeated rounds of RAMP™.
We understand what is important to you. Fusion Antibodies can offer a complete range of services from antibody humanization, affinity maturation and stable expression. You may choose to include/exclude as many stages as you would like from your final package. Our goal is to develop the best possible antibodies using our custom package of services to support your development pathway.
We offer a royalty free antibody humanization service built on the success of 100+ projects. Our CDRx™ platform enables a robust, reliable and accurate modernized version of the CDR grafting technique.
Fusion Antibodies' transient expression services are your first choice for high quality and reliable recombinant protein expression in mammalian or bacterial systems.
Feel free to get in touch for any further information. We would love to hear from you.Contact Us